How I learned to stop worrying and love the placebo effect
April 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials, feature, pharma, placebo effect
Louis Goss talks to Harvard Medical School placebo expert Dr Ted Kaptchuk in asking what the placebo effect means for …
CHMP recommendation for bluebird bio’s gene therapy in β-thalassaemia
April 1, 2019Research and Development, Sales and Marketing Bluebird Bio, CHMP, EMA, Zynteglo, gene therapy, β-thalassaemia
Massachusetts-based bluebird bio has taken a significant leap forward in its pursuit of regulatory authorisation for its first gene therapy, …
Indian authorities say J&J’s baby shampoo contains ‘harmful ingredients’
April 1, 2019Sales and Marketing Cancer, India, J&J, JJ, Johnson & Johnson, Rajasthan, baby shampoo, formaldehyde
Indian authorities in the state of Rajasthan have said that samples taken from Johnson & Johnson’s baby shampoo contained ‘harmful …
Novartis inks $1.6 billion deal with immunology biotech IFM Therapeutics
April 1, 2019Sales and Marketing Atlas Venture, Boston, IFM Therapeutics, Novartis, pharma
Swiss firm Novartis has agreed to pay a sum of $310 million upfront to Boston inflammation specialist IFM Therapeutics, as …
Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer
April 1, 2019Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma, tecentriq
Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of …
Lyrica to be made class C drug in Northern Ireland
April 1, 2019Sales and Marketing Lyrica, Northern Ireland, class c, illegal drugs, pain, pregabalin
Pregabalin – sold under the brand name Lyrica – will now be treated as a class C drug in Northern …
AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration
March 29, 2019Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Daiichi Sankyo, pharma
AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see …
Top Ten most popular articles on Pharmafile.com this week!
March 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
A Japanese journalist was ordered to pay Â¥3.3 million to an anti-vaccine researcher, this week, after a court found her …
England’s antidepressant prescriptions double to 70m in a decade
March 29, 2019Medical Communications England, UK, antidepressants, anxiety, depression, pharma
Figures released by NHS Digital have revealed that prescriptions for antidepressants in the UK have risen to 70.9 million, almost …
ABPI calls for temporary export ban in effort to prevent shortages in case of no-deal Brexit
March 29, 2019Medical Communications ABPI, UK, brexit, drug shortages, export market
The Association of the British Pharmaceutical Industry (ABPI) has called for a temporary ban on exports as a means of …
Sacklers fraudulently transferred funds to dodge litigation, lawsuit says
March 29, 2019Medical Communications Litigation, New York, OxyContin, Purdue Pharma, Sackelr, opioids
New York state prosecutors have filed a lawsuit against members of the Sackler family, alleging the Purdue Pharma controllers fraudulently …
Vertex destroyed nearly 8,000 packs of Orkambi in 2018
March 28, 2019Medical Communications, Sales and Marketing Briatin, Orkambi, UK, Vertex, cystic fibrosis
Vertex destroyed nearly 8,000 packs of the $272,000 a year cystic fibrosis drug Orkambi in 2018, the company said in …
Working Life: Dr Paul-Peter Tak, ex-Senior Vice President, Development Lead and Chief Immunology Officer at GSK, Venture Partner at Flagship Pioneering
March 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Working Life, feature
Dr Paul-Peter Tak, ex-Senior Vice President, Development Lead and Chief Immunology Officer at GSK, Venture Partner at Flagship Pioneering.How did …
J&J’s antihistamine-releasing contact lens shows promise in Phase 3 trials
March 28, 2019Research and Development J&J, JJ, eye care, pharma
Johnson and Johnson has unveiled new Phase 3 data on its antihistamine-releasing contact lens, showing that the investigational product led …
AMR advisor calls for public utility company to tackle AMR
March 28, 2019Medical Communications, Research and Development AMR, Lord Jim O'Neill, antimicrobial resistance, pharma, public health
Lord Jim O’Neill, an economist and former government advisor on antimicrobial resistance (AMR), has accused the pharmaceutical industry of “spewing …
AstraZeneca’s Imfinzi to be made available via Cancer Drugs Fund in England
March 28, 2019Sales and Marketing AstraZeneca, Cancer, Imfinzi, NHS, NICE, UK, lung cancer
AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will now be made available to English lung cancer patients on the NHS via the …
Gilead accused of ripping off US taxpayers
March 28, 2019Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents
Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in …
Japanese court orders public health campaigner to pay ¥3.3 million to anti-vaccine researcher
March 27, 2019Medical Communications, Research and Development HPV, Japan, anti vaxx, anti-vaccine, public health, vaccines
Dr Riko Muranaka, a researcher and journalist who has campaigned against misinformation surrounding vaccines, has been ordered to pay Â¥3.3 …
Measles outbreak spurs New York County to ban all unvaccinated children from public spaces
March 27, 2019Research and Development New York, US, pharma, vaccination, vaccines
Rockland County, New York State, is taking serious measures to combat its biggest measles outbreak in decades, making the decision …
Japan awards AbbVie’s Skyrizi with first approval, in 4 psoriasis indications
March 27, 2019Research and Development, Sales and Marketing AbbVie, Japan, Skyrizi, pharma, psoriasis
AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
